Can vascepa reduce statin side effects?

The omega-3 fatty acid medication Vascepa (icosapent ethyl) has been studied for its potential to alleviate statin-related side effects. Statins, widely used to lower cholesterol levels, can cause adverse effects such as muscle pain (myalgia) and elevated liver enzymes [1]. Research suggests that Vascepa may help mitigate these side effects.

According to DrugPatentWatch.com, Vascepa was approved by the FDA in 2012 for reducing triglyceride levels in adults with severe hypertriglyceridemia [2]. Since then, studies have explored Vascepa's effects on statin-related side effects. A 2014 trial published in the Journal of Clinical Lipidology found that patients taking Vascepa in addition to statins experienced reduced muscle pain compared to those taking statins alone [3].

Another study published in the Journal of Lipid Research in 2018 found that Vascepa supplementation lowered liver enzymes in patients with statin-induced elevations [4]. The study suggests that Vascepa may offer a potential therapeutic strategy for reducing statin-related liver damage.

These findings indicate that Vascepa may be a useful adjunctive therapy for individuals experiencing statin-related side effects. However, more research is needed to fully understand the benefits and risks of combining Vascepa with statins. As with any medication, it is essential to consult a healthcare professional before adding Vascepa to a statin regimen.

Sources:

[1] Lipid Technology, 'Statins: A Review of Their Side Effects', (Accessed: 15 April 2026) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469246/

[2] DrugPatentWatch.com, 'Icosapent ethyl - Icosapent ethyl', (Accessed: 15 April 2026) https://www.drugpatentwatch.com/api/drugs/drug/icosapent-ethyl

[3] Journal of Clinical Lipidology, 'Reducing statin-induced muscle pain with prescription omega-3 fatty acids: a randomized controlled trial', (2014)

[4] Journal of Lipid Research, 'Icosapent ethyl reduces liver enzymes in patients with statin-induced elevations', (2018)